News | October 03, 2012

Sharp Memorial Investigates Radio Frequency as Possible Treatment for Chronic High Blood Pressure

Hospital is leading trial site in Southern California for randomized trial

October 3, 2012 — When multiple medications prove ineffective, patients with high blood pressure are currently left with few treatment options. Sharp Memorial Hospital was the first on the West Coast to participate in Medtronic's SYMPLICITY HTN-3 clinical trial in March, and is currently the leading trial site in Southern California, to test an experimental medical device that aims to lower high blood pressure by using radio frequency energy to disrupt hyperactive nerves that contribute to the condition.

High blood pressure affects an estimated 40 percent of adults in the United States and can lead to serious heart, kidney and blood vessel damage. Traditional treatments for the condition include oral medications that are meant to be taken on a daily basis for years at a time. These drugs are ineffective in some patients, leaving their high blood pressure dangerously uncontrolled.

In the SYMPLICITY HTN-3 trial, interventional cardiologists thread a small tube in the groin and place a device in the artery leading to the kidney. The device briefly emits radio frequency near renal nerves in an attempt to disrupt hyperactive nerves that may be the root of high blood pressure. Renal nerves communicate information from the kidney to the brain, and vice versa. In people with hypertension, the renal nerves are overactive. Multiple treatments are performed in each artery before the device is removed and, since the procedure is minimally invasive, the patient will typically go home the next day.

"Many of our patients in this trial would not otherwise receive treatment for their high blood pressure," said Raghava Gollapudi, M.D., an interventional cardiologist affiliated with Sharp Memorial. "Medications currently on the market are effective in the great majority of people suffering from hypertension. However, for the small percentage of people who aren't being helped by these pills, SYMPLICITY HTN-3 may be an option."

Principal investigators Gollapudi and Ron Miller, M.D., affiliated with Sharp Memorial Hospital, are currently evaluating patients for the SYMPLICITY HTN-3 trial. The trial is randomized.

For more information: www.sharp.com/memorial

Related Content

Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Overlay Init